EUVIMEDEUVIMED entdecken
Crossref

Overall survival in TP53-mutated AML and MDS

Christian J Puzo, Karl M Hager, Henry M Rinder, Olga K Weinberg, Alexa J Siddon

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06054-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Christian J Puzo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TP53 mutations in patients with AML and MDS frequently portend a poor prognosis, related to both p53 allele status and blast count. In 2022, the ICC and WHO released updated guidelines for classifying p53-mutated AML/MDS. The characteristics of p53 mutations, their associated co-mutations, and their effects on overall survival (OS) are not known in the context of these new guidelines. A retrospective chart review was undertaken for all patients with AML or MDS and at least one TP53 mutation detected on next generation sequencing (NGS) at Yale New Haven Hospital from 2015 to 2023. All patients (N = 210) met criteria for one of the 5 diagnostic classes based on WHO and ICC guidelines. Kaplan-Meier curves with associated log-rank testing and Cox proportional hazards model quantified the effects of clinical and molecular data on survival. Multi-hit pathogenic mutations were related to poorer OS in MDS but not AML using either the WHO (p = .02) or the ICC (p = .01) diagnostic criteria. The most significant predictors of OS in the sample overall were platelet count < 50 K (HR: 2.01, 95% CI [1.47, 2.75], p < .001) and TP53 VAF ≤ 40% (HR: 0.68, 95% CI[0.50, 0.91], p = .01). Blast count ranges, complex karyotype, and p53 mutation type or location, showed no association with OS. In our cohort defined by the 2022 ICC and WHO criteria, VAF and thrombocytopenia, rather than blast count or p53 mutation features, significantly predicted OS. These results speak to each criteria's ability to identify cases of similarly aggressive disease biology and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMutationTumor Suppressor Protein p53HumansFemaleMaleMiddle AgedAgedRetrospective StudiesAged, 80 and overAdultSurvival RateHigh-Throughput Nucleotide SequencingPrognosis

Stichwörter der Autor:innen

AMLICCMDSMulti-hitTP53WHO

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT, USA.
  • Department of Laboratory Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Laboratory Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA. Alexa.siddon@yale.edu.
  • Department of Pathology, Yale School of Medicine, New Haven, CT, USA. Alexa.siddon@yale.edu.

Zitieren

APA

Puzo, C. J., Hager, K. M., Rinder, H. M., Weinberg, O. K., & Siddon, A. J. (2024). Overall survival in TP53-mutated AML and MDS. Annals of Hematology. https://doi.org/10.1007/s00277-024-06054-7

Vancouver

Puzo CJ, Hager KM, Rinder HM, Weinberg OK, Siddon AJ. Overall survival in TP53-mutated AML and MDS. Annals of Hematology. 2024. doi:10.1007/s00277-024-06054-7

BibTeX
@article{Puzo2024,
  author = {Puzo, Christian J and Hager, Karl M and Rinder, Henry M and Weinberg, Olga K and Siddon, Alexa J},
  title = {Overall survival in TP53-mutated AML and MDS},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06054-7}
}
Kostenlos starten →